The pre-specified primary endpoint was the change-from-baseline between the placebo and active groups in the Yale Global Tic Severity Scale (YGTSS) at Week 6 in the intent-to-treat (ITT)
Under the terms of the agreement, ImmunoGen received a $25 million upfront payment for IMGN529/Debio 1562 and is entitled to a $5 million milestone payment to be paid
The American biotech company said that its DNA vaccine combination had produced some of the highest overall levels of immune response rates ever recorded in the history of
This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.
This sets out the Competition and Markets Authority’s (CMA) provisional decision that MSD operated an anti-competitive discount scheme for its medicine Remicade. Remicade is the brand name for
Actemra is the first therapy approved by the FDA for the treatment of adult patients with GCA. This is the sixth FDA approval for Actemra since the medicine
The two companies will explore the anti-cancer activity of NKTR-214 with five different targeted mechanisms in preclinical tumor models of lymphoma, melanoma and colorectal cancer. "We look forward
The collaboration will identify small molecules which efficiently inhibit an important and highly conserved ubiquitin protein. Proteorex will receive an undisclosed upfront payment, and downstream milestone-based payments. Corbin
The financing was led by new investor Arix Bioscience plc, and included Pivotal bioVenture Partners, Advent Life Sciences, Domain Associates and Bay City Capital. All of Iterum’s current
Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor. This BLA includes data from pivotal studies in patients with episodic and chronic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.